Adriaan Cleton

Adriaan Cleton

Auto-generated profile, based on publicly available information

Adriaan Cleton

Bayer AG, Berlin, Germany

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
MVMarc Vermeir
Marc Vermeir
INIneke Naessens
Ineke Naessens
BRBart Remmerie
Bart Remmerie
GMGeert Mannens
Geert Mannens
JHJan Hendrickx
Jan Hendrickx
ACAdriaan Cleton
Adriaan Cleton
Absorption, metabolism, and excretion of paliperidone, an atypical antipsychotic, was studied in five healthy male subjects after a single dose of 1 mg of [14C]paliperidone oral solution (∼16 μCi/subject). One week after dosing, 88.4 to 93.8% (mean 91.1%) of the administered radioactivity was excreted: 77.1 to 87.1% (mean 79.6%) in urine and 6.8 to 14.4% (mean 11.4%) in the feces. Paliperidone was the major circulating compound (97% of the area under the plasma concentration-time curve at 24 h). No metabolites could be detected in plasma. Renal excretion was the major route of elimination with 59% of the dose excreted unchanged in urine. About half of the renal excretion occurred by active secretion. Unchanged drug was not detected in feces. Four metabolic pathways were identified as being involved in the elimination of paliperidone, each of which accounted for up to a maximum of 6.5% of the biotransformation of the total dose. Biotransformation of the drug occurred through oxidative N-dealkylation (formation of the acid metabolite M1), monohydroxylation of the alicyclic ring (M9), alcohol dehydrogenation (formation of the ketone metabolite M12), and benzisoxazole scission (formation of M11), the latter in combination with glucuronidation (M16) or alicyclic hydroxylation (M10). Unchanged drug, M1, M9, M12, and M16 were detected in urine; M10 and M11 were detected in feces. The monohydroxylated metabolite M9 was solely present in urine samples of extensive CYP2D6 metabolizers, whereas M10, another metabolite monohydroxylated at the alicyclic ring system, was present in feces of poor metabolizers as well. In conclusion, paliperidone is not metabolized extensively and is primarily renally excreted.

18 December 2012 in Analytical Chemistry
Verified
Journal Article
Closed access
HNHendrik Neubert
Hendrik Neubert
DMDavid Muirhead
David Muirhead
MKMusarat Kabir
Musarat Kabir
CGChris Grace
Chris Grace
ACAdriaan Cleton
Adriaan Cleton
RARosalin Arends
Rosalin Arends

1 September 2007 in International Clinical Psychopharmacology
Verified
Journal Article
Closed access
RLRemy Luthringer
Remy Luthringer
LSLuc Staner
Luc Staner
NNNadine Noel
Nadine Noel
MMMuriel Muzet
Muriel Muzet
CGCristiana Gassmann-Mayer
Cristiana Gassmann-Mayer
JPJoseph M. Palumbo
Joseph M. Palumbo
The effects of paliperidone extended-release on sleep architecture in patients with schizophrenia-related insomnia were evaluated in this multicenter, double-blind, randomized, placebo-controlled study. Patients received paliperidone extended-release 9 mg/day or matching placebo during the 14-day double-blind phase. Sleep architecture and sleep continuity were evaluated using polysomnograms. Subjective sleep measures were evaluated daily using the Leeds Sleep Evaluation Questionnaire. Efficacy and safety were also assessed. Thirty-six patients (17 on paliperidone extended-release, 19 on placebo; mean age 32.2 years) completed the study. Paliperidone extended-release treatment vs. placebo resulted in clinically and statistically significant differences in sleep measurements from baseline to endpoint including a reduction in: persistent sleep latency (41 min), sleep onset latency (35 min), number of awakenings after sleep onset (7), time awake in bed (50 min), and stage 1 sleep duration (12 min); prolongation in: total sleep time (53 min), sleep period time (42 min), stage 2 sleep duration (51 min), and rapid eye movement sleep duration (18 min); and an increase in sleep efficiency index (11%). Paliperidone extended-release, compared with placebo, did not exacerbate daytime somnolence and improved symptoms of schizophrenia. Paliperidone extended-release was well tolerated and improved sleep architecture and sleep continuity in patients diagnosed with schizophrenia and concomitant insomnia.

1 January 2004 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CSChad L Stoner
Chad L Stoner
ACAdriaan Cleton
Adriaan Cleton
KJKjell Johnson
Kjell Johnson
DODoo-Man Oh
Doo-Man Oh
HHHussein Hallak
Hussein Hallak
HHHyo-Kyung Han
Hyo-Kyung Han

29 November 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
MGMichael Gerisch
Michael Gerisch
FHFrank-Thorsten Hafner
Frank-Thorsten Hafner
DLDieter Lang
Dieter Lang
MRMartin Radtke
Martin Radtke
KDKonstanze Diefenbach
Konstanze Diefenbach
JLJohn Lettieri
John Lettieri
To evaluate the mass balance, metabolic disposition, and pharmacokinetics of a single dose of regorafenib in healthy volunteers. In addition, in vitro metabolism of regorafenib in human hepatocytes was investigated.

3 April 2014 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ACAdriaan Cleton
Adriaan Cleton
SRStefaan Rossenu
Stefaan Rossenu
HCHerta Crauwels
Herta Crauwels
JBJoris Berwaerts
Joris Berwaerts
DHDavid Hough
David Hough
CFClara M. Rosso Fernández
Clara M. Rosso Fernández